By inhibiting glucagon production, GLP-1 receptor agonists help maintain lower blood glucose levels, preventing unwanted spikes
It has only recently entered the market, so we will likely see an increase in use over the coming years
Key considerations when switching: Allow a washout period based on tirzepatide half-life Start retatrutide at the standard 1mg initiation dose regardless of previous tirzepatide dose Expect renewed GI side effects as the glucagon receptor is a new stimulus Monitor heart rate more carefully during the initial escalation period When tirzepatide is the better choice Tirzepatide remains the superior option in several specific situations
The decision to switch is personalized, considering individual health profiles, weight loss goals, lifestyle, and cost-effectiveness, ensuring the most suitable and affordable approach for each patient
From a pharmacy and regulatory perspective, what will be just as important as the therapy itself is how platforms operationalize this at scaleensuring appropriate patient selection, monitoring, and state-by-state compliance as demand continues to surge
J.MalikD.RichesonA
